VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better …
Topic:
bausch,
-
-
Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting
by Your NewsFive Presentations Will Highlight Findings from the XIPERE® Pivotal Phase 3 Program VAUGHAN, ON, July 6, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global …
-
Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors
by Your NewsVAUGHAN, ON, June 23, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better …
-
“Using our proprietary technologies for spherical, multifocal, toric and multifocal toric lenses, Revive™ custom soft lenses will allow eye care professionals to use one customizable soft contact lens for a …
-
First-Quarter 2022 Financial Results Revenues of $889 Million GAAP Net Income of $20 Million Adjusted EBITDA (non-GAAP)1 of $170 Million Bausch + Lomb Commenced Trading Under “BLCO” Ticker Reported Revenues Grew …
-
Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association’s Optometry’s Meeting
by Your NewsSeven Presentations Will Include Unique Research on the New Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost Lubricant Eye Drops Company to Also Host Several Sponsored Education Events VAUGHAN, …
-
Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution
by Your News“Building on our successful Biotrue® Multi-Purpose Solution brand, we developed Biotrue® Hydration Plus to meet the needs of patients who depend on their contact lenses for the majority of the day …
-
New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don’t Wait
by Your NewsCampaign Includes Educational Social Media Posts to Broaden Patient Awareness of Cataract Surgery and Care During Cataract Awareness Month VAUGHAN, ON, June 2, 2022 — Bausch + Lomb Corporation (NYSE/TSX: …
-
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
by Your NewsVAUGHAN, ON, May 13, 2022 — Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, …
-
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
by Your NewsLAVAL, QC and VAUGHAN, ON, May 10, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”) and Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) today announced the …
-
Bausch + Lomb Begins Trading under “BLCO” on NYSE and TSX Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better VAUGHAN, ON, …
-
By Niket Nishant (Reuters) -Bausch + Lomb was valued at $6.48 billion in its U.S. market debut on Friday as the eye-care company’s shares opened nearly 3% above an offer …
-
LAVAL, QC and VAUGHAN, ON, May 5, 2022 — Bausch + Lomb Corporation (“Bausch + Lomb”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …
-
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
by Your NewsNOV03 Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction in Both Phase 3 Trials VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, …
-
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
by Your News13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, …
-
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
by Your NewsLAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that, in connection with its previously announced intention …
-
LAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch + Lomb Corporation (“Bausch + Lomb”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …
-
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
by Your NewsNOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, April 25, 2022 — Bausch + Lomb, a leading …
-
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
by Your NewsVAUGHAN, ON and LAVAL, QC and TRENTON, N.J., April 21, 2022 — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …
-
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
by Your NewsThe Term Loan Facility is expected to mature in 2027. The Revolving Credit Facility is expected to mature in 2027 and to be undrawn at closing of the proposed initial …
-
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
by Your News“Bausch + Lomb is committed to supporting continuous scientific exchange designed to help surgeons get the most out of our current technologies and better understand the potential of those in …
-
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
by Your News“XIPERE® is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients who struggle with macular edema associated with uveitis, which is …